SANDKI 360° powered by MIXMOVE
17.1.2023 11:30:00 EET | Business Wire | Press release
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary healthcare products.
The network offers healthcare temperature-controlled transport for parcels and 1 to 5 pallet(s) shipments throughout 25 countries. Skandi Network is composed of 7 members who are all leading healthcare carriers. The main challenge of the network is to operate cross border transport shipments that involve cross docking operations.
“Having end-to-end visibility is already a challenge with one carrier but operating multi-county and multi-carrier operations at the same time is even more challenging. As we are transporting temperature sensitive healthcare products, we must guarantee that the products are transported in alignment with the GDP regulation and that temperature is monitored and always guaranteed. It is also important that our customers can have access to that information in real time.” -Rudy Smets, CEO of Skandi Network.
For these reasons, Skandi Network teamed up with MIXMOVE to develop a unique collaborative platform - Skandi 360° - to consolidate all operational and analytical data flows for all shipments going through the network.
One view and one access to the best-in-class healthcare transport network in Europe
Skandi Network is about giving access to the best-in-class healthcare transport network in Europe, working with 7 domestic leading freight forwarders. Skandi 360° will provide a coordinated solution to the market and its different stakeholders, giving them real time access and control of the first pan-European healthcare transport network (having over 4,780 vehicles and 165 temperature-controlled depots).
Connecting to Skandi 360° will allow them to expand, and/or optimise, their own capacities in a consolidated approach.
CO2 emissions reduction
In addition, Skandi 360° will also give an opportunity to reduce the carbon footprint and the cost of ownership throughout the whole transport chain. This includes:
- Consolidation of flows,
- Optimisation of logistics networks via regional distribution centres,
- No additional passive packaging needed in the network,
- And a reduction of damages and product loss during transport thanks to temperature monitoring.
Digitalising Logistics with MIXMOVE
MIXMOVE can integrate a very large amount of information and data coming from different sources and IT systems (like TMS, telematic systems, WMS, ERP). The MIXMOVE technology turns vertical and independent data flows into a flexible and consolidated One view/One access to data, all the way up to parcel/shipment level.
MIXMOVE also makes it possible to combine transport network functionalities and collaborative platform functionalities. This enables the management of the transport network in a lean and efficient way, creating real added value for all users of Skandi Network.
MIXMOVE tailors its technology to suit specific constraints linked to the healthcare transport business, including the regulations around integrating quality management, real-time temperature follow-up (including corrective and preventive actions), and POD’s that include an end-to-end temperature curve.
“We have chosen MIXMOVE for their proven expertise in the global supply chain and their proven technology to manage complex transport network operations. They use an advanced cloud-based technology with API connectivity. The MIXMOVE solution offers a capability to connect different systems and different tools (TMS, WMS, telematic systems…) seamlessly to the platform. This is what we needed, first to allow all members to be connected, and second to allow all external stakeholders, such as logistic service providers, to plug themselves into the platform and use our network." – Rudy Smets, CEO of Skandi Network.
About Skandi Network
Skandi Network is the first unified network for healthcare distribution throughout Europe for human & veterinary pharmaceuticals, biomedicals, APIs, temperature sensitive medical devices, diagnostics and general life products that are temperature sensitive. The network provides 2/8°C, 15/25°C and 20°C (in passive packaging) transport services and covers 25 countries thanks to the alliance of 7 leading healthcare carriers : Arra Group (Poland), BHS Logistics (Denmark, Sweden, Norway, Finland, Estonia, Latvia, Lithuania), BL Turkey Biopharma Logistics (Turkey), Eurotranspharma (France, Belgium, the Netherlands, Luxemburg, Spain, Czech Republic, Slovakia and also Germany, Austria and Slovenia via its existing local partner), Movianto (England, Scotland, Wales, Northern Ireland), PHSE (Italy), Rangel Logistics Solutions (Portugal). The aim of Skandi Network is to have members covering 36 countries by 2025. In total, the network members have more than 4,000 employees, operating in more than 4,780 temperature-controlled vehicles, 10 strategic regional consolidation platforms, 165 temperature controlled depots and transporting 14,750,000 temperature controlled shipments per year.
For more information : https://www.skandi-network.com/
About MIXMOVE
MIXMOVE provides a cloud solution supporting logistics by connecting systems, increasing profitability and reducing CO2 emissions.
For more than 10 years, MIXMOVE provides shippers, carriers and logistics service providers, the best customer experience in getting logistics transparency, predictability and resilience.
The main capabilities of the solution are focused on visibility, control and execution of transport & logistics services. Additional capabilities include optimising warehouse operations (like advanced cross-docking), order flow and fulfilment optimisation, planning automatisation, dispatching and routing optimisation.
MIXMOVE mobile applications enable digitalisation and collaboration with drivers. Trusted by customers like 3M, Volkswagen TPS, DHL, DSV, and Gebrüder Weiss, MIXMOVE has a proven track record in delivering high ROI, facilitating collaboration and helping achieve sustainability by improving resource utilisation.
For more information about MIXMOVE: www.mixmove.io
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230117005252/en/
Contact information
Rudy SMETS
CEO
mail@skandi-network.com
Dorothée DOSSMANN
Head of Marketing
dorothee.dossmann@mixmove.io
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 202624.10.2026 11:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data from multiple differentiated investigational medicines across its priority solid tumor disease areas at the European Society for Medical Oncology (ESMO) Congress 2026 (October 23–27, Madrid). The presentations span gastrointestinal, lung, and breast cancers, and reflect the growing momentum of BeOne’s solid tumor franchise. Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “At ESMO, we are showing how our strategy of matching the right modality to disease biology is translating into meaningful clinical progress. Our GPC3 x 4-1BB bispecific antibody continues to be well tolerated and demonstrates durable activity with longer follow up in patients with heavily pre-treated hepatocellular carcinoma, while the first clinical data from our brain-penetrant PRMT5 inhibitor and CEA-targeting ADC expand our innovation in non-small cell lung cancer. Alongsi
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 20:42:00 EEST | Press release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 17:19:00 EEST | Press release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 17:15:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 16:00:00 EEST | Press release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
